lurasidone / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 23 Diseases   12 Trials   12 Trials   1306 News 


«12345678910111213...1415»
  • ||||||||||  lurasidone / Generic mfg.
    Sleep Disturbance in Maintenance Treatment for Schizophrenia: Effect of Residual Symptoms (Spadolini Pavilion Upper Floor) -  Mar 11, 2022 - Abstract #SIRS2022SIRS_162;    
    P3
    There was a significant correlation between “reduced sleep” and daytime sleepiness ESS total score (P = 0.006). Week-6 change in “reduced sleep” symptom significantly mediated changes in symptom severity (as assessed by PANSS total and subscale scores) as well as changes in the UPSA-B score and ranked CogState cognitive composite score with lurasidone or quetiapine XR treatment (vs.
  • ||||||||||  Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
    Current Issues and Expected Challenges in Identification of Depression As a Cardinal Symptom within Bipolar Disorder (In-person & Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_1179;    
    The current standard of care is associated with limited efficacy and numerous adverse effects. With prevalence continuing to rise, it is incumbent for relevant stakeholders to develop methods to distinguish bipolar depression and manage the disease with increased efficacy and safety to reduce morbidity and mortality.
  • ||||||||||  Vraylar (cariprazine) / Mitsubishi Tanabe, Recordati, Gedeon Richter, AbbVie
    Healthcare Resource Use Among Patients Treated with Lurasidone or Cariprazine for Depressive Episodes Associated with Bipolar I Disorder (In-person & Virtual) -  Mar 8, 2022 - Abstract #ISPOR2022ISPOR_612;    
    With prevalence continuing to rise, it is incumbent for relevant stakeholders to develop methods to distinguish bipolar depression and manage the disease with increased efficacy and safety to reduce morbidity and mortality. In this study, patients with depressive episodes associated with BPD-1 treated with lurasidone or cariprazine had low rates of IP and ER visits; HRU for BPD-1-related hospitalization and number of OP visits was lower for patients taking lurasidone compared to patients on cariprazine.
  • ||||||||||  lurasidone / Generic mfg.
    Trial completion date, Trial primary completion date:  Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia" (clinicaltrials.gov) -  Mar 4, 2022   
    P=N/A,  N=300, Recruiting, 
    The overall paucity of trials and of adequate controls indicates that more well-designed randomized controlled trials are required for adequate assessment of antipsychotic drug treatment for juveniles. Trial completion date: Nov 2021 --> Apr 2022 | Trial primary completion date: Nov 2021 --> Apr 2022
  • ||||||||||  lurasidone / Generic mfg.
    Clinical, Journal:  Bilateral pedal edema associated with lurasidone: a case report. (Pubmed Central) -  Dec 25, 2021   
    Resolution of the edema after discontinuation of lurasidone indicates that the edema may have been caused by lurasidone. Caution should be needed when prescribing lurasidone for patients, as pedal edema may affect patients' adherence to the prescription.
  • ||||||||||  lurasidone / Generic mfg.
    Clinical, Retrospective data, Journal:  Efficacy of Lurasidone in Antipsychotic-Naive vs. Antipsychotic-Exposed Adolescents with Schizophrenia: Post-Hoc Analysis of a Two-Year, Open-Label Study. (Pubmed Central) -  Dec 25, 2021   
    Short-term and long-term treatment with lurasidone demonstrated significant improvement in manic symptoms and was not associated with an increased risk of TEM in either adult or pediatric patient populations compared to rates reported in clinical populations of patients. In this post-hoc analysis of a 2-year study, adolescents with schizophrenia who had received no previous antipsychotic therapy showed greater improvement compared to previously treated patients during both short- and long-term treatment with lurasidone.
  • ||||||||||  lurasidone / Generic mfg.
    Clinical, Journal:  Long-Term Effectiveness of Lurasidone in Pediatric Bipolar Depression: Response, Remission and Recovery. (Pubmed Central) -  Dec 25, 2021   
    In this post-hoc analysis of a 2-year study, adolescents with schizophrenia who had received no previous antipsychotic therapy showed greater improvement compared to previously treated patients during both short- and long-term treatment with lurasidone. In children and adolescents with bipolar depression, up to 2 years of treatment with lurasidone was associated with continued improvement in depressive symptoms, resulting in progressively higher rates of response, remission, recovery, and the more rigorously calculated outcome of sustained remission.
  • ||||||||||  Use Of Metformin To Attenuate Bmi Changes Associated With Second-Generation Antipsychotic Use In The Youth In The Care, Child, And Adolescent Population () -  Dec 18, 2021 - Abstract #AACAP2021AACAP_732;    
    The odds of increasing the BMI z score among patients in the control group were 2.39 times higher than the odds for those in the metformin group (β = 1.243; SE = 0.425; OR = 3.466; 95% CI, 1.32-4.84; p < 0.003). For a 1-point increase in the BMI z score weight difference among youth-in-care in the metformin group, there is a 2.39 increase in the BMI z score weight among youth-in-care in the control group.Conclusions The addition of metformin for patients on a second-generation antipsychotic within the youth-in-care population led to decreased change in BMI z score when compared to their matched subjects.APS, PRE, OBE
  • ||||||||||  lurasidone / Generic mfg.
    Clinical, Journal:  Efficacy and safety of lurasidone in children and adolescents: Recommendations for clinical management and future research. (Pubmed Central) -  Dec 16, 2021   
    With little effects on hormones and weight gain, potential procognitive profile due to its 5-HT7 antagonism, and reduced extrapyramidal side effects, lurasidone could be a good choice in terms of both effectiveness and tolerability, particularly for patients headed towards a long-term treatment. This article aims to summarize the available scientific evidence from the literature on the use of lurasidone in children and adolescents and to provide recommendations for clinical management and future research.
  • ||||||||||  lurasidone / Generic mfg.
    Understanding Negative Symptoms in Clinical Trials of Acute Schizophrenia ([VIRTUAL]) -  Nov 28, 2021 - Abstract #ACNP2021ACNP_1004;    
    We propose a novel prognostic enrichment strategy to select patients on the basis of a greater likelihood of having a specified negative symptom construct (MPNS) in order to provide the basis to demonstrate specific treatment benefit on negative symptoms. The analytical approaches piloted here with already-conducted clinical trials, can be prospectively defined as analyses in clinical trials of acute exacerbation of schizophrenia, to facilitate the characterization of compounds with non-D2 mechanisms of action.
  • ||||||||||  lurasidone / Generic mfg.
    Impaired Coping in Rats Exposed to Chronic Mild Stress: Modulatory Effect of Chronic Lurasidone Treatment ([VIRTUAL]) -  Nov 28, 2021 - Abstract #ACNP2021ACNP_923;    
    We find that composite GLX signal from plasma differentiates antipsychotic-naive patients from HC with very high accuracy. Although not significant after correction for multiplicity, our findings suggest that the GLX signal may partially map onto core symptom domains, i.e. positive and negative symptoms in schizophrenia spectrum patients.
  • ||||||||||  lurasidone / Generic mfg.
    Impaired Coping in Rats Exposed to Chronic Mild Stress: Modulatory Effect of Chronic Lurasidone Treatment (Exhibit Hall C) -  Nov 28, 2021 - Abstract #ACNP2021ACNP_583;    
    We find that composite GLX signal from plasma differentiates antipsychotic-naive patients from HC with very high accuracy. Although not significant after correction for multiplicity, our findings suggest that the GLX signal may partially map onto core symptom domains, i.e. positive and negative symptoms in schizophrenia spectrum patients.
  • ||||||||||  lurasidone / Generic mfg.
    Clinical, Review, Journal:  Antipsychotic medication for women with schizophrenia spectrum disorders. (Pubmed Central) -  Nov 17, 2021   
    Given the protective effects of oestrogens on the course of SSD, oestrogen replacement therapy should be considered for postmenopausal patients, who are more vulnerable to side-effects and yet require higher dosages of most antipsychotics to reach similar efficacy. In conclusion, there is a need for tailored, female-specific prescription guidelines, which take into account adjustments required across different phases of life.
  • ||||||||||  risperidone / Generic mfg., lurasidone / Generic mfg.
    Retrospective data, Journal, Real-world evidence:  Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study. (Pubmed Central) -  Nov 12, 2021   
    Similarly, treatment with aripiprazole (OR =1.61, 95% CI 1.08-2.38) and olanzapine (OR =1.73, CI:1.06-2.80) was associated with significantly higher odds of psychiatric hospitalizations compared to lurasidone, but treatment with quetiapine (OR =1.02, CI: 0.68-1.54) or risperidone (OR =1.01, CI: 0.67-1.51) was not. In usual clinical care, pediatric patients with bipolar disorder treated with lurasidone had a significantly lower risk of all-cause and psychiatric hospitalizations when compared to aripiprazole and olanzapine, but not quetiapine or risperidone.
  • ||||||||||  lurasidone / Generic mfg.
    Journal:  Harnessing the potential of nanostructured formulations to mimic the food effect of lurasidone. (Pubmed Central) -  Oct 14, 2021   
    In vivo pharmacokinetic evaluations revealed that the nanosuspension, nano-emulsion and SLH enhanced the bioavailability of lurasidone by 3-fold, 2.4-fold and 8.8-fold, respectively, compared to pure drug after oral administration. For lurasidone, the combination of lipid-based nanostructure and porous silica nanostructure (SLH) led to optimal fasted state bioavailability which can ultimately result in enhanced treatment efficacy, easier dosing regimens and improved patient outcomes.
  • ||||||||||  lurasidone / Generic mfg.
    Clinical, Journal:  A missed case of lurasidone induced laryngospasm: A case study and overview of extrapyramidal symptom identification and treatment. (Pubmed Central) -  Oct 13, 2021   
    For lurasidone, the combination of lipid-based nanostructure and porous silica nanostructure (SLH) led to optimal fasted state bioavailability which can ultimately result in enhanced treatment efficacy, easier dosing regimens and improved patient outcomes. With increased management of bipolar disorder in the primary care setting and increased use of atypical antipsychotics as the primary therapy for bipolar disorder, it is essential that all practitioners are prepared to actively monitor for EPS, followed by its rapid diagnosis and treatment.
  • ||||||||||  lithium carbonate ER / Generic mfg.
    Trial completion, HEOR:  Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies (clinicaltrials.gov) -  Oct 7, 2021   
    P=N/A,  N=1037352, Completed, 
    With increased management of bipolar disorder in the primary care setting and increased use of atypical antipsychotics as the primary therapy for bipolar disorder, it is essential that all practitioners are prepared to actively monitor for EPS, followed by its rapid diagnosis and treatment. Enrolling by invitation --> Completed
  • ||||||||||  amitriptyline / Generic mfg., alprazolam / Generic mfg., lurasidone / Generic mfg.
    [VIRTUAL] Mitragynine/Kratom as a Cause of Death in a Forensic Case () -  Sep 18, 2021 - Abstract #CAP2021CAP_659;    
    With the increasing reports of death from an overdose of mitragynine (alone or in combination with other drugs), rapid screening methods should be developed in addition to the sophisticated gas chromatography. Our case also highlights the need for more studies regarding the toxicity of mitragynine, development of consensus as to the lethal dose, and treatment of overdose and withdrawal.